IS8161A - Píperidín-sambönd og lyfjablöndur sem innihalda thau - Google Patents

Píperidín-sambönd og lyfjablöndur sem innihalda thau

Info

Publication number: IS8161A
Authority: IS; Iceland
Prior art keywords: piperidine compound; animal; disclosed; piperidine compounds; thau
Prior art date: 2003-07-24

Application number

IS8161A

Other languages

English (en)

Other versions

IS2684B (is

Inventor

Sun Qun

Xin Wen Kate

Zhou Xiaoming

Original Assignee

Euro-Celtique S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-24

Filing date

2005-12-01

Publication date

2005-12-01

2005-12-01 Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.

2005-12-01 Publication of IS8161A publication Critical patent/IS8161A/is

2010-10-15 Publication of IS2684B publication Critical patent/IS2684B/is

Links

150000003053 piperidines Chemical class 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
-1 Piperidine Compound Chemical class 0.000 abstract 3
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 3
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
208000012661 Dyskinesia Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000007101 Muscle Cramp Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
208000027089 Parkinsonian disease Diseases 0.000 abstract 1
206010034010 Parkinsonism Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
208000017442 Retinal disease Diseases 0.000 abstract 1
206010038923 Retinopathy Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
208000025865 Ulcer Diseases 0.000 abstract 1
206010047700 Vomiting Diseases 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000003925 brain function Effects 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
206010027175 memory impairment Diseases 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000001823 pruritic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
231100000397 ulcer Toxicity 0.000 abstract 1
230000008673 vomiting Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)

IS8161A 2003-07-24 2005-12-01 Píperidín-efnasambönd og lyfjablöndur sem innihalda þau IS2684B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48951503P	2003-07-24	2003-07-24
PCT/US2004/023912 WO2005009987A1 (en)	2003-07-24	2004-07-23	Piperidine compounds and pharmaceutical compositions containing them

Publications (2)

Publication Number	Publication Date
IS8161A true IS8161A (is)	2005-12-01
IS2684B IS2684B (is)	2010-10-15

Family

ID=34102892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8161A IS2684B (is)	2003-07-24	2005-12-01	Píperidín-efnasambönd og lyfjablöndur sem innihalda þau

Country Status (28)

Country	Link
US (2)	US7572812B2 (is)
EP (2)	EP2067776A1 (is)
JP (1)	JP4686456B2 (is)
KR (2)	KR100977242B1 (is)
CN (2)	CN101914088A (is)
AT (1)	ATE430741T1 (is)
AU (1)	AU2004259357B2 (is)
BR (1)	BRPI0412808A (is)
CA (1)	CA2533509C (is)
CY (1)	CY1109273T1 (is)
DE (1)	DE602004020994D1 (is)
DK (1)	DK1648878T3 (is)
EA (1)	EA010852B1 (is)
ES (1)	ES2326979T3 (is)
GE (1)	GEP20094676B (is)
HR (1)	HRP20090404T1 (is)
IL (3)	IL173343A (is)
IS (1)	IS2684B (is)
MA (1)	MA27983A1 (is)
MX (1)	MXPA06000941A (is)
NO (1)	NO20060910L (is)
NZ (1)	NZ545506A (is)
PL (1)	PL1648878T3 (is)
PT (1)	PT1648878E (is)
SI (1)	SI1648878T1 (is)
UA (1)	UA84710C2 (is)
WO (1)	WO2005009987A1 (is)
ZA (1)	ZA200509562B (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60234812D1 (de)	2001-01-29	2010-02-04	Shionogi & Co	Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US7157462B2 (en) *	2002-09-24	2007-01-02	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
MY142655A (en) *	2003-06-12	2010-12-15	Euro Celtique Sa	Therapeutic agents useful for treating pain
SI1867644T1 (sl)	2003-07-24	2009-10-31	Euro Celtique Sa	Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
US7572914B2 (en)	2003-12-19	2009-08-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
WO2006023931A2 (en)	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
US7713973B2 (en)	2004-10-15	2010-05-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
AU2006247487A1 (en) *	2005-05-12	2006-11-23	Amgen Inc.	Antipyretic agents against VR1-antagonist-induced increases in body temperature
DE102005023943A1 (de)	2005-05-20	2006-11-23	Grünenthal GmbH	Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
GEP20135728B (en)	2006-10-09	2013-01-25	Takeda Pharmaceuticals Co	Kinase inhibitors
CA2685121A1 (en)	2007-04-27	2008-11-06	Purdue Pharma L.P.	Therapeutic agents useful for treating pain
DK2142529T3 (da)	2007-04-27	2014-02-10	Purdue Pharma Lp	Trpv1-antagonister og anvendelser deraf
AU2011226773C1 (en) *	2007-04-27	2012-07-26	Purdue Pharma L.P.	TRPV1 antagonists and uses thereof
US8084616B2 (en)	2007-10-24	2011-12-27	Abbott Laboratories	TRPV1 antagonists
KR101449785B1 (ko)	2008-04-21	2014-10-14	오토노미, 인코포레이티드	귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en)	2008-04-21	2024-04-30	Dompé Farmaceutici S.P.A.	Auris formulations for treating otic diseases and conditions
EP2306975A4 (en)	2008-07-21	2012-10-31	Otonomy Inc	COMPOSITIONS WITH A TAXED RELEASE FOR MODULATING THE EARM STRUCTURE AND THE BORN IMMUNE SYSTEM, AND METHODS OF TREATING EAR OR DISEASE
US8759362B2 (en) *	2008-10-24	2014-06-24	Purdue Pharma L.P.	Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8703962B2 (en) *	2008-10-24	2014-04-22	Purdue Pharma L.P.	Monocyclic compounds and their use as TRPV1 ligands
WO2010064597A1 (ja) *	2008-12-01	2010-06-10	武田薬品工業株式会社	ピペリジン誘導体
CN102098080B (zh) *	2009-12-09	2014-07-02	京信通信系统（中国）有限公司	数字微波射频拉远覆盖系统及方法
CN102753019A (zh)	2009-12-15	2012-10-24	纽罗普公司	用于治疗神经系统病症的化合物
JP5876423B2 (ja) *	2010-06-22	2016-03-02	塩野義製薬株式会社	Ｔｒｐｖ１阻害活性を有する化合物とその使用
EP2709609B1 (en) *	2011-05-17	2017-10-04	Shionogi & Co., Ltd.	Heterocyclic compounds
SG10201605163PA (en)	2011-06-22	2016-08-30	Purdue Pharma Lp	Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013021276A1 (en)	2011-08-10	2013-02-14	Purdue Pharma L.P.	Trpv1 antagonists including dihydroxy substituent and uses thereof
US20170250927A1 (en) *	2013-12-23	2017-08-31	Dali Systems Co. Ltd.	Virtual radio access network using software-defined network of remotes and digital multiplexing switches
WO2016046130A1 (en)	2014-09-22	2016-03-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of fibrosis
US10913053B2 (en) *	2016-03-04	2021-02-09	California Institute Of Technology	Germanosilicate compositions and methods of preparing the same
CA2937365C (en)	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
JP7033789B2 (ja)	2016-06-29	2022-03-11	オトノミー，インク．	トリグリセリド耳用製剤とその使用
CN113990502B (zh) *	2021-10-28	2024-08-06	浙江大学	一种基于异构图神经网络的icu心衰预测系统
CN114259055A (zh) *	2021-11-02	2022-04-01	郑州和合生物工程技术有限公司	一种拮抗幽门螺旋杆菌的组合物
DE102022104759A1 (de)	2022-02-28	2023-08-31	SCi Kontor GmbH	Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
KR102826412B1 (ko) *	2022-11-01	2025-06-26	차의과학대학교 산학협력단	N-노닐데옥시노지리마이신을 포함하는 피부 가려움증의 억제, 경감, 개선, 또는 치료를 위한 조성물

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US556837A (en) *		1896-03-24		Lifting device
US556838A (en) *		1896-03-24		Marking-tag
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4409229A (en)	1977-12-02	1983-10-11	Hoechst-Roussel Pharmaceuticals, Inc.	Antidepressive and tranquilizing substituted 1,3-dihydrospiro[benzo(c)thiophene]s
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
DE3440141A1 (de)	1984-11-02	1986-05-07	Heiner Dipl.-Chem. Dr. 8000 München Eckert	Verwendung von kohlensaeure-bis-trichlormethylester als proreagens fuer phosgen
US5316759A (en)	1986-03-17	1994-05-31	Robert J. Schaap	Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4797419A (en)	1986-11-03	1989-01-10	Warner-Lambert Company	Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
DE3822792C2 (de)	1987-07-11	1997-11-27	Sandoz Ag	Neue Verwendung von 5HT¶3¶-Antagonisten
US5198459A (en)	1987-07-11	1993-03-30	Sandoz Ltd.	Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US4866197A (en)	1987-12-23	1989-09-12	American Home Products Corporation	Production of N-((2-alkoxy-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)carbonyl)-N-methylglycine esters
US4853384A (en)	1988-03-14	1989-08-01	Hoechst-Roussel Pharmaceuticals Inc.	1-carbonyl derivatives of 4-aryl-4-aryloxypiperidines
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5075341A (en)	1989-12-01	1991-12-24	The Mclean Hospital Corporation	Treatment for cocaine abuse
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
SI9111010B (sl)	1990-06-07	2005-02-28	Astrazeneca Ab	3,5-disubstituirani indolni derivati kot "5-HT1-podobni" receptorski agonisti
US5698155A (en)	1991-05-31	1997-12-16	Gs Technologies, Inc.	Method for the manufacture of pharmaceutical cellulose capsules
US6204284B1 (en)	1991-12-20	2001-03-20	American Cyanamid Company	Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5232934A (en)	1992-07-17	1993-08-03	Warner-Lambert Co.	Method for the treatment of psychomotor stimulant addiction
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US5321012A (en)	1993-01-28	1994-06-14	Virginia Commonwealth University Medical College	Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5556837A (en)	1994-08-01	1996-09-17	Regeneron Pharmaceuticals Inc.	Methods for treating addictive disorders
US5762925A (en)	1994-11-03	1998-06-09	Sagen; Jacqueline	Preventing opiate tolerance by cellular implantation
ATE301457T1 (de)	1995-06-12	2005-08-15	Searle & Co	Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
FR2744448B1 (fr) *	1996-02-02	1998-04-24	Pf Medicament	Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
US5891889A (en)	1996-04-03	1999-04-06	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
EP0944388A4 (en)	1996-04-03	2001-08-16	Merck & Co Inc	INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
JP2001511764A (ja) *	1996-04-12	2001-08-14	住友製薬株式会社	ピペリジニルピリミジン誘導体
FR2758328B1 (fr) *	1997-01-15	1999-04-02	Pf Medicament	Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
FR2758327B1 (fr)	1997-01-15	1999-04-02	Pf Medicament	Nouvelles arylpiperazines derivees de piperidine
EP1009804B1 (en)	1997-08-20	2003-10-29	The Regents of the University of California	Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
US6455550B1 (en)	1997-08-22	2002-09-24	Hoffmann-La Roche Inc.	N-alkanoylphenylalanine derivatives
KR100615760B1 (ko) *	1997-08-22	2006-08-25	에프. 호프만-라 로슈 아게	엔-알카노일페닐알라닌 유도체
WO1999037304A1 (en)	1998-01-27	1999-07-29	Aventis Pharmaceuticals Products Inc.	SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
EP0943683A1 (en)	1998-03-10	1999-09-22	Smithkline Beecham Plc	Human vanilloid receptor homologue Vanilrep1
GB9907097D0 (en)	1999-03-26	1999-05-19	Novartis Ag	Organic compounds
EP1183238A1 (en)	1999-05-17	2002-03-06	Eli Lilly And Company	Metabotropic glutamate receptor antagonists
GB9912411D0 (en)	1999-05-28	1999-07-28	Pfizer Ltd	Compounds useful in therapy
AU7514700A (en) *	1999-09-07	2001-04-10	Syngenta Participations Ag	Cyanopiperidines
WO2001021577A2 (en) *	1999-09-20	2001-03-29	Takeda Chemical Industries, Ltd.	Melanin concentrating hormone antagonist
US6887870B1 (en)	1999-10-12	2005-05-03	Bristol-Myers Squibb Company	Heterocyclic sodium/proton exchange inhibitors and method
JP2003531202A (ja)	2000-04-25	2003-10-21	ファルマシア・コーポレーション	３，４−ジ（カルボシクリルまたはヘテロシクリル）チオフェンの位置選択的合成
US6544981B2 (en)	2000-06-09	2003-04-08	Bristol-Myers Squibb Company	Lactam inhibitors of factor Xa and method
WO2001095856A2 (en) *	2000-06-15	2001-12-20	Chaconne Nsi Co., Ltd.	Urea derivative useful as an anti-cancer agent and process for preparing same
ES2251512T3 (es) *	2000-08-31	2006-05-01	F. Hoffmann-La Roche Ag	Derivados de quinazolina como antagonista adrenergicos alfa-1.
WO2002048098A1 (en)	2000-12-15	2002-06-20	Japan Science And Technology Corporation	Arylbis (perfluoroalkylsulfonyl) methane, metal salt of the same, and processes for producing these
US7193113B2 (en)	2000-12-15	2007-03-20	Japan Science And Technology Corporation	Arylbis(perfluoroalkylsulfonyl) methane and metallic salt thereof, and methods for producing the same
JP4280073B2 (ja)	2001-04-12	2009-06-17	ファーマコペイアドラッグディスカバリー，インコーポレイテッド	Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン
US20040259912A1 (en)	2001-09-28	2004-12-23	Takahiro Matsumoto	Benzine derivatives, process for preparing the same and use thereof
EP1458385A4 (en)	2001-12-19	2005-12-21	Merck & Co Inc	METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
US7390813B1 (en)	2001-12-21	2008-06-24	Xenon Pharmaceuticals Inc.	Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
GB0209715D0 (en)	2002-04-27	2002-06-05	Astrazeneca Ab	Chemical compounds
EP2508204B1 (en) *	2002-06-26	2014-09-24	Ono Pharmaceutical Co., Ltd.	Remedies for diseases caused by vascular contraction or dilation
IL165862A0 (en)	2002-06-28	2006-01-15	Euro Celtique Sa	Therapeutic piperazine derivatives useful for tre ating pain
US7157462B2 (en)	2002-09-24	2007-01-02	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
TWI349671B (en)	2002-09-27	2011-10-01	Dainippon Sumitomo Pharma Co	Novel adenine derivative and its use
DE10252666A1 (de)	2002-11-11	2004-08-05	Grünenthal GmbH	N-Piperidyl-cyclohexan-Derivate
US7223788B2 (en)	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
ATE556067T1 (de)	2003-05-20	2012-05-15	Ajinomoto Kk	Modulatoren des vanilloid rezeptors
MY142655A (en)	2003-06-12	2010-12-15	Euro Celtique Sa	Therapeutic agents useful for treating pain
US7129235B2 (en)	2003-07-11	2006-10-31	Abbott Laboratories	Amides useful for treating pain
US20050009841A1 (en)	2003-07-11	2005-01-13	Zheng Guo Zhu	Novel amides useful for treating pain
CN1902178A (zh)	2003-12-30	2007-01-24	欧洲凯尔特公司	用于治疗疼痛的哌嗪

2004
- 2004-07-23 UA UAA200601979A patent/UA84710C2/ru unknown
- 2004-07-23 WO PCT/US2004/023912 patent/WO2005009987A1/en not_active Ceased
- 2004-07-23 EA EA200600201A patent/EA010852B1/ru not_active IP Right Cessation
- 2004-07-23 KR KR1020077024527A patent/KR100977242B1/ko not_active Expired - Fee Related
- 2004-07-23 JP JP2006521294A patent/JP4686456B2/ja not_active Expired - Fee Related
- 2004-07-23 BR BRPI0412808-7A patent/BRPI0412808A/pt not_active IP Right Cessation
- 2004-07-23 NZ NZ545506A patent/NZ545506A/xx not_active IP Right Cessation
- 2004-07-23 SI SI200431187T patent/SI1648878T1/sl unknown
- 2004-07-23 HR HR20090404T patent/HRP20090404T1/xx unknown
- 2004-07-23 KR KR1020067001686A patent/KR100954415B1/ko not_active Expired - Fee Related
- 2004-07-23 EP EP09156594A patent/EP2067776A1/en not_active Withdrawn
- 2004-07-23 GE GEAP20049181A patent/GEP20094676B/en unknown
- 2004-07-23 DE DE602004020994T patent/DE602004020994D1/de not_active Expired - Lifetime
- 2004-07-23 EP EP04779120A patent/EP1648878B9/en not_active Expired - Lifetime
- 2004-07-23 AT AT04779120T patent/ATE430741T1/de active
- 2004-07-23 CN CN2010102296810A patent/CN101914088A/zh active Pending
- 2004-07-23 ES ES04779120T patent/ES2326979T3/es not_active Expired - Lifetime
- 2004-07-23 PL PL04779120T patent/PL1648878T3/pl unknown
- 2004-07-23 CN CNA2004800214151A patent/CN1829708A/zh active Pending
- 2004-07-23 CA CA2533509A patent/CA2533509C/en not_active Expired - Fee Related
- 2004-07-23 AU AU2004259357A patent/AU2004259357B2/en not_active Ceased
- 2004-07-23 PT PT04779120T patent/PT1648878E/pt unknown
- 2004-07-23 MX MXPA06000941A patent/MXPA06000941A/es active IP Right Grant
- 2004-07-23 DK DK04779120T patent/DK1648878T3/da active
2005
- 2005-11-28 ZA ZA200509562A patent/ZA200509562B/en unknown
- 2005-12-01 IS IS8161A patent/IS2684B/is unknown
2006
- 2006-01-20 US US11/337,271 patent/US7572812B2/en not_active Expired - Fee Related
- 2006-01-24 IL IL173343A patent/IL173343A/en not_active IP Right Cessation
- 2006-02-07 MA MA28781A patent/MA27983A1/fr unknown
- 2006-02-24 NO NO20060910A patent/NO20060910L/no not_active Application Discontinuation
2009
- 2009-07-20 US US12/506,040 patent/US8349842B2/en not_active Expired - Lifetime
- 2009-08-04 CY CY20091100827T patent/CY1109273T1/el unknown
2010
- 2010-04-06 IL IL204885A patent/IL204885A/en not_active IP Right Cessation
- 2010-04-06 IL IL204884A patent/IL204884A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE602004020994D1 (de)	2009-06-18
IL173343A (en)	2011-09-27
EP1648878B9 (en)	2011-03-16
ES2326979T3 (es)	2009-10-22
JP2006528642A (ja)	2006-12-21
US20100210686A1 (en)	2010-08-19
CY1109273T1 (el)	2014-07-02
SI1648878T1 (sl)	2009-10-31
EA200600201A1 (ru)	2006-06-30
PT1648878E (pt)	2009-07-23
CN1829708A (zh)	2006-09-06
CA2533509C (en)	2011-02-22
ZA200509562B (en)	2006-08-30
KR100977242B1 (ko)	2010-08-24
NZ545506A (en)	2009-11-27
HRP20090404T1 (hr)	2009-08-31
EA010852B1 (ru)	2008-12-30
EP1648878B1 (en)	2009-05-06
KR100954415B1 (ko)	2010-04-26
EP1648878A1 (en)	2006-04-26
IL204884A0 (en)	2011-08-01
AU2004259357A1 (en)	2005-02-03
US7572812B2 (en)	2009-08-11
DK1648878T3 (da)	2009-08-10
MXPA06000941A (es)	2006-03-30
KR20060037399A (ko)	2006-05-03
AU2004259357B2 (en)	2010-02-18
UA84710C2 (ru)	2008-11-25
BRPI0412808A (pt)	2006-09-26
HK1089755A1 (en)	2006-12-08
CA2533509A1 (en)	2005-02-03
PL1648878T3 (pl)	2009-10-30
MA27983A1 (fr)	2006-07-03
EP2067776A1 (en)	2009-06-10
IL173343A0 (en)	2006-06-11
GEP20094676B (en)	2009-05-10
IS2684B (is)	2010-10-15
JP4686456B2 (ja)	2011-05-25
CN101914088A (zh)	2010-12-15
IL204885A (en)	2011-09-27
WO2005009987A1 (en)	2005-02-03
IL204884A (en)	2011-10-31
KR20070107189A (ko)	2007-11-06
US8349842B2 (en)	2013-01-08
ATE430741T1 (de)	2009-05-15
US20060199824A1 (en)	2006-09-07
NO20060910L (no)	2006-04-04

Publication	Publication Date	Title
IS8161A (is)	2005-12-01	Píperidín-sambönd og lyfjablöndur sem innihalda thau
CY1109318T1 (el)	2014-07-02	Eτεροαρυλο-τετραϋδροπιπεριδυλικες ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου
AU2003212882A8 (en)	2003-09-02	2 - piperazine - pyridines useful for treating pain
MY142655A (en)	2010-12-15	Therapeutic agents useful for treating pain
CY1110004T1 (el)	2015-01-14	Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του αλγους
CY1109056T1 (el)	2014-07-02	Παραγωγα 2-πυριδιν αλκυνιου χρησιμα για την αγωγη του πονου